Washington, United States — British-Swedish drugmaker AstraZeneca on Wednesday revised down by three percentage points the effectiveness of its new coronavirus vaccine after American authorities raised concerns that results reported from its US trial were outdated.
The company now says its vaccine is 76 rather than 79 percent effective at preventing any kind of symptomatic new coronavirus disease.
It remains 100 percent effective against severe COVID-19, it added.
The move came after an independent panel of experts appointed to supervise the trial expressed concern that AstraZeneca had failed to include updated data in its initially released figure.
The US National Inst…
Keep on reading: AstraZeneca says vaccine 76% effective in updated US trial data